×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GSK – glaxosmithkline plc (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GSK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/23
01:13 pm
gsk
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
Low
Report
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
2/20
01:01 pm
gsk
GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Barclays PLC.
2/18
08:00 am
gsk
GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows
Low
Report
GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows
2/9
02:11 pm
gsk
GSK (NYSE:GSK) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
GSK (NYSE:GSK) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
2/9
09:12 am
gsk
GSK (NYSE:GSK) had its "hold" rating reaffirmed by analysts at TD Cowen.
Low
Report
GSK (NYSE:GSK) had its "hold" rating reaffirmed by analysts at TD Cowen.
1/27
05:12 am
gsk
GSK (NYSE:GSK) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating on the stock.
Low
Report
GSK (NYSE:GSK) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating on the stock.
1/21
10:00 am
gsk
GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026
Low
Report
GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026
1/20
09:00 am
gsk
GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million
Low
Report
GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/12
8 Best Pharmaceutical Stocks to Buy for Income [Yahoo! Finance News]
6.6%
3/3 GlaxoSmithKline Reportedly Trying Again to Sell Antibiotics Line [The Motley Fool] 5.1%
3/2 Form 6-K GLAXOSMITHKLINE PLC For: Mar 02 4.9%
4/16 UPDATE 2-'Too early' to lift UK lockdown but coronavirus outbreak peaking, minister says [Reuters] 3.7%
3/24 Form 6-K GLAXOSMITHKLINE PLC For: Mar 24 3.7%
7/24 REFILE-UPDATE 1-GSK predicts smaller fall in 2019 profit after standout quarter for Shingrix [Reuters] 2.5%
5/21 What Older Adults Need To Know About Measles And Shingles Vaccines [Forbes] 2.3%
7/19 Inside The Pharmaceutical Lobby's Campaign For More Government Subsidies Through Medicare Part D [Forbes] 2.2%
4/8 Gilead: Upside From Potential Coronavirus Treatment Could Dissipate [Seeking Alpha] 2.1%
6/6 Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options 2.1%
3/3 GlaxoSmithKline Reportedly Trying Again to Sell Antibiotics Line [The Motley Fool] 5.1%
3/2 Form 6-K GLAXOSMITHKLINE PLC For: Mar 02 4.9%
4/16 UPDATE 2-'Too early' to lift UK lockdown but coronavirus outbreak peaking, minister says [Reuters] 3.7%
3/24 Form 6-K GLAXOSMITHKLINE PLC For: Mar 24 3.7%
7/24 REFILE-UPDATE 1-GSK predicts smaller fall in 2019 profit after standout quarter for Shingrix [Reuters] 2.5%
5/21 What Older Adults Need To Know About Measles And Shingles Vaccines [Forbes] 2.3%
7/19 Inside The Pharmaceutical Lobby's Campaign For More Government Subsidies Through Medicare Part D [Forbes] 2.2%
4/8 Gilead: Upside From Potential Coronavirus Treatment Could Dissipate [Seeking Alpha] 2.1%
6/6 Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options 2.1%
TOP News Decliners
3/20
Form 6-K GLAXOSMITHKLINE PLC For: Mar 20
-3.9%
3/6 Form 20-F GLAXOSMITHKLINE PLC For: Dec 31 -3.9%
3/2 Here's Why Shares of AnaptysBio Jumped Today [The Motley Fool] -3.8%
4/15 UPDATE 1-The world will need more than one COVID-19 vaccine, GSK CEO says [Reuters] -3.2%
2/23 Better Buy: GlaxoSmithKline vs. Eli Lilly [The Motley Fool] -2.9%
10/1 GlaxoSmithKline (GSK) Presents At ESMO Congress 2019 - Slideshow [Seeking Alpha] -2.6%
2/5 GlaxoSmithKline plc (GSK) CEO Emma Walmsley on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -2.6%
4/28 Better Buy: Inovio Pharmaceuticals vs. GlaxoSmithKline [The Motley Fool] -2.5%
5/13 Form 6-K GLAXOSMITHKLINE PLC For: May 13 -2.4%
5/7 UPDATE 1-UK Stocks-Factors to watch on May 7 [Reuters] -2.3%
3/6 Form 20-F GLAXOSMITHKLINE PLC For: Dec 31 -3.9%
3/2 Here's Why Shares of AnaptysBio Jumped Today [The Motley Fool] -3.8%
4/15 UPDATE 1-The world will need more than one COVID-19 vaccine, GSK CEO says [Reuters] -3.2%
2/23 Better Buy: GlaxoSmithKline vs. Eli Lilly [The Motley Fool] -2.9%
10/1 GlaxoSmithKline (GSK) Presents At ESMO Congress 2019 - Slideshow [Seeking Alpha] -2.6%
2/5 GlaxoSmithKline plc (GSK) CEO Emma Walmsley on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -2.6%
4/28 Better Buy: Inovio Pharmaceuticals vs. GlaxoSmithKline [The Motley Fool] -2.5%
5/13 Form 6-K GLAXOSMITHKLINE PLC For: May 13 -2.4%
5/7 UPDATE 1-UK Stocks-Factors to watch on May 7 [Reuters] -2.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: